-
Mashup Score: 2Novel chemoimmunotherapy approach shows promise for B-cell acute lymphoblastic leukemia in phase 1 study at Fred Hutch - 12 hour(s) ago
In the first clinical trial of dose-adjusted EPOCH along with inotuzumab ozogamicin (InO) in adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), Fred Hutch Cancer Center researchers found this combination was well tolerated and produced a high overall response rate (83%).
Source: www.fredhutch.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Innovators Network Happy Hour - 14 hour(s) ago
Fred Hutch Cancer Center’s Innovators Network invites you to join us for a free event to hear the latest updates from researchers working to understand the cancer risk factors and barriers to care that impact the LGBTQIA+ community so we can better serve patients here and everywhere.
Source: www.fredhutch.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Forward Together - 1 day(s) ago
A breast cancer breakthroughs fundraising event, where you’ll learn about the progress our dedicated physician-scientists have made for today’s patients and the discoveries they’re pursuing for tomorrow’s.
Source: www.fredhutch.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 36
Nearly 25 years after arriving at Fred Hutch Cancer Center for his hematology-oncology fellowship, Bart Scott, MD, has been named the Miklos Kohary and Natalia Zimonyi Kohary Endowed Chair, established to support myelodysplastic syndrome research.
Source: www.fredhutch.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2GeekWire Awards 2024 revealed: Winners bask in momentum of AI and potential of region - 3 day(s) ago
GeekWire co-founders Todd Bishop, left, and John Cook open the 2024 GeekWire Awards at Showbox SoDo in Seattle on Thursday. (GeekWire Photo / Kevin
Source: www.geekwire.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 17Novel chemoimmunotherapy approach shows promise for B-cell acute lymphoblastic leukemia in phase 1 study at Fred Hutch - 3 day(s) ago
In the first clinical trial of dose-adjusted EPOCH along with inotuzumab ozogamicin (InO) in adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), Fred Hutch Cancer Center researchers found this combination was well tolerated and produced a high overall response rate (83%).
Source: www.fredhutch.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4DAISY nursing award, launched at Fred Hutch, turns 25 - 3 day(s) ago
The DAISY Award for nursing provides crucial recognition for nurses and helps combat the heartbreak and compassion fatigue that can come with caring for those who are suffering. The DAISY, now in its 25th year, started at Fred Hutch; its founders joined us for Nurses’ Week.
Source: www.fredhutch.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 7Obliteride - 4 day(s) ago
Fred Hutch Obliteride is a bike ride and 5K that empowers people to help cure cancer faster by raising funds for Fred Hutchinson Cancer Center.
Source: www.obliteride.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 7Obliteride - 4 day(s) ago
Fred Hutch Obliteride is a bike ride and 5K that empowers people to help cure cancer faster by raising funds for Fred Hutchinson Cancer Center.
Source: www.obliteride.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Outstanding people are the Heart of the Hutch - 5 day(s) ago
We have been profiling people who illustrate the culture and spirit of Fred Hutch with the Heart of the Hutch series. This edition focuses on our outstanding clinicians, administration employees and patient-facing staff.
Source: www.fredhutch.orgCategories: General Medicine News, Onc News and JournalsTweet
New study from @RyanCassaday et al. published in @JAMAOnc found DA-EPOCH plus inotuzumab ozogamicin was “safe and highly active” in adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). https://t.co/4WNbuwy6Qp